Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Biotalys NV is an agricultural technology company developing protein-based biocontrol solutions for sustainable crop protection. The company specializes in biofungicides and bioinsecticides that target pests and pathogens such as botrytis, powdery mildew, anthracnose, leafspot diseases, oomycetes, and alternaria in fruits, vegetables, legumes, and specialty crops. Its proprietary AGROBODY Foundry technology platform generates these innovative protein-based products, offering precise alternatives to conventional chemical pesticides while minimizing environmental impact and ensuring safety for farmers and consumers. Biotalys NV advances a pipeline including EVOCA for first-generation and next-generation biofungicides, BIOFUN-6, BIOFUN-7, BIOFUN-4, BIOFUN-8, and BioIns-2 against key insect pests. These solutions address crop protection from soil to post-harvest, aiming to reduce food waste and improve yield quality across the food value chain. Founded in 2013 and headquartered in Ghent, Belgium, Biotalys NV plays a pivotal role in the AgTech sector by pioneering precision biocontrols for safer food production.
€3.15
€0.04 (-1.10%)
EOD Jun 23, 2026 · Twelve Data
ROIC dropped from -33.26% to -51.79%, capital efficiency is deteriorating. Negative free cash flow of -€14M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€0.00
Net Income (TTM)
-€16M
▼ -19.5% YoY
Op. Margin
—
ROIC
-51.79%
▼ -18.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€14M
▼ -8.4% YoY
Op. Cash Flow (TTM)
-€14M
▼ -8.1% YoY
Net Debt
-€4M
Net Cash Position
Cash & Equiv.
€8M
Continue Research
Biotalys NV (BTLS.XBRU)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Biotalys NV scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Biotalys NV scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -51.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BTLS.XBRU's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.